You are here

  • Home
  • Archive
  • Volume 78, Issue Suppl 2
  • FRI0106 SARILUMAB AND TOCILIZUMAB RECEPTOR OCCUPANCY (RO), AND EFFECTS ON C-REACTIVE PROTEIN (CRP) LEVELS, IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA)

Article info

Article menu

Download PDFPDF

Poster Presentations
Friday, 14 June 2019
Rheumatoid arthritis – biological DMARDs
FRI0106 SARILUMAB AND TOCILIZUMAB RECEPTOR OCCUPANCY (RO), AND EFFECTS ON C-REACTIVE PROTEIN (CRP) LEVELS, IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA)
Free

Authors

Citation

Xu C, Nolain P, Lu Q, et al
FRI0106 SARILUMAB AND TOCILIZUMAB RECEPTOR OCCUPANCY (RO), AND EFFECTS ON C-REACTIVE PROTEIN (CRP) LEVELS, IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA)
Annals of the Rheumatic Diseases 2019;78:719-720.

Publication history

  • First published May 27, 2019.
Online issue publication 
May 27, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.